Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 9/2011

Open Access 01-09-2011 | Review Article

The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin’s and non-Hodgkin’s lymphoma survivors: a systematic review

Authors: Simone Oerlemans, Floortje Mols, Marten R. Nijziel, Marnix Lybeert, Lonneke V. van de Poll-Franse

Published in: Annals of Hematology | Issue 9/2011

Login to get access

Abstract

Cancer survivors are at risk of experiencing adverse physical and psychosocial effects of their cancer and its treatment. Both Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL) survivors face problems that can affect their health-related quality of life (HRQoL). The authors systematically reviewed the literature on HRQoL among HL and NHL survivors. A PubMed and PsychINFO literature search for original articles published until May 2011 was performed. Twenty-four articles, which met the predefined inclusion criteria, were subjected to a quality checklist. HL survivors showed the most problems in (role) physical, social and cognitive functioning, general health, fatigue and financial problems. In addition, HL survivors treated with a combination of therapies, with older age and female sex reported worse HRQoL. NHL survivors showed the most problems in physical functioning, appetite loss, vitality and financial problems. Having had chemotherapy was negatively associated with HRQoL, but no differences in chemotherapy regimens were found. Furthermore, in NHL survivors not meeting public exercise guidelines, HRQoL is low but can be improved with more exercise. More research on the longitudinal comparison between HL and NHL survivors and healthy controls should be performed in order to better understand the long-term (side) effects of treatment on HRQoL and possibilities to alleviate these.
Literature
1.
2.
Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (2010) SEER Cancer Statistics Review, 1975–2008, National Cancer Institute, Bethesda, MD. http://​seer.​cancer.​gov/​csr/​1975_​2008/​. Accessed 10 May 2011
3.
Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint A, Kotlum JE, Olafsdottir E, Pukkala E, Storm HH (2010) NORDCAN—Cancer Incidence, Mortality, Prevalence and Prediction in the Nordic Countries, version 3.6. Association of the Nordic Cancer Registries. Danish Cancer Society (http://​www.​ancr.​nu). Accessed 7 Feb 2011
4.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Canc 127(12):2893–2917CrossRef
5.
6.
Fobair P, Hoppe RT, Bloom J, Cox R, Varghese A, Spiegel D (1986) Psychosocial problems among survivors of Hodgkin’s disease. J Clin Oncol 4(5):805–814PubMed
7.
Geffen DB, Blaustein A, Amir MC, Cohen Y (2003) Post-traumatic stress disorder and quality of life in long-term survivors of Hodgkin’s disease and non-Hodgkin’s lymphoma in Israel. Leuk lymphoma 44(11):1925–1929PubMedCrossRef
8.
Knobel H, Loge J, Brit Lund M, Forfang K, Nome O, Kaasa S (2001) Late medical complications and fatigue in Hodgkin’s disease survivors. J Clin Oncol 19(13):3226–3233PubMed
9.
Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S (1999) Reduced health-related quality of life among Hodgkin’s disease survivors: a comparative study with general population norms. Ann Oncol 10(1):71–77PubMedCrossRef
10.
Hess SL, Johannsdottir IM, Hamre H, Kiserud CE, Loge JH, Fossa SD (2011) Adult survivors of childhood malignant lymphoma are not aware of their risk of late effects. Acta oncologica, Stockholm
11.
Mols F, Aaronson NK, Vingerhoets AJ, Coebergh JW, Vreugdenhil G, Lybeert ML, van de Poll-Franse LV (2007) Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study. Cancer 109(8):1659–1667PubMedCrossRef
12.
Arden-Close E, Pacey A, Eiser C (2010) Health-related quality of life in survivors of lymphoma: a systematic review and methodological critique. Leuk lymphoma 51(4):628–640PubMedCrossRef
13.
Mols F, Vingerhoets AJ, Coebergh JW, van de Poll-Franse LV (2005) Quality of life among long-term breast cancer survivors: a systematic review. Eur J Canc 41(17):2613–2619CrossRef
14.
Den Oudsten BL, Van Heck GL, De Vries J (2007) Quality of life and related concepts in Parkinson’s disease: a systematic review. Mov Disord 22(11):1528–1537CrossRef
15.
Goodman KA, Riedel E, Serrano V, Gulati S, Moskowitz CH, Yahalom J (2008) Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin’s lymphoma. J Clin Oncol 26(32):5240–5247PubMedCrossRef
16.
Heutte N, Flechtner HH, Mounier N, Mellink WA, Meerwaldt JH, Eghbali H, van't Veer MB, Noordijk EM, Kluin-Nelemans JC, Lampka E, Thomas J, Lugtenburg PJ, Viterbo L, Carde P, Hagenbeek A, van der Maazen RW, Smit WG, Brice P, van Marwijk Kooy M, Baars JW, Poortmans P, Tirelli U, Leeksma OC, Tomsic R, Feugier P, Salles G, Gabarre J, Kersten MJ, Van Den Neste E, Creemers GJ, Gaillard I, Meijnders P, Tertian G, Reman O, Muller HP, Troncy J, Blanc M, Schroyens W, Voogt PJ, Wijermans P, Rieux C, Ferme C, Henry-Amar M (2009) Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. The lancet oncology 10(12):1160–1170PubMedCrossRef
17.
Jerkeman M, Kaasa S, Hjermstad M, Kvaloy S, Cavallin-Stahl E (2001) Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial. Med oncol 18(1):85–94PubMedCrossRef
18.
Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139–144PubMed
19.
Ware JE, Kosinski MA (2001) SF-36® physical and mental health summary scales: a manual for users of version 1, 2nd edn. QualityMetric Inc, Lincoln
20.
Ware JE, Kosinski MA, Dewey JE (2000) How to score version 2 of the SF-36 health survey. Quality Metric Inc., Lincoln
21.
Norman GR, Sloan JA, Wyrwich KW (2003) Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Medical care 41(5):582–592PubMed
22.
Brandt J, Dietrich S, Meissner J, Neben K, Ho AD, Witzens-Harig M (2010) Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy. Leuk lymphoma 51(11):2012–2020PubMedCrossRef
23.
Ganz PA, Moinpour CM, Pauler DK, Kornblith AB, Gaynor ER, Balcerzak SP, Gatti GS, Erba HP, McCoy S, Press OW, Fisher RI (2003) Health status and quality of life in patients with early-stage Hodgkin’s disease treated on Southwest Oncology Group Study 9133. J Clin Oncol 21(18):3512–3519PubMedCrossRef
24.
Gil-Fernandez J, Ramos C, Tamayo T, Tomas F, Figuera A, Arranz R, Martinez-Chamorro C, Fernandez-Ranada M (2003) Quality of life and psychological well-being in Spanish long-term survivors of Hodgkin’s disease: results of a controlled pilot study. Ann Hematol 82(1):14–18PubMed
25.
Greil R, Holzner B, Kemmler G, Kopp M, Buchowski A, Oberaigner W, Fritsch E, Dirnhofer S, Rueffer U, Diehl V, Sperner-Unterweger B (1999) Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin’s disease from 1969 to 1994. Eur J Cancer 35(5):698–706PubMedCrossRef
26.
Hjermstad MJ, Oldervoll L, Fossa SD, Holte H, Jacobsen AB, Loge JH (2006) Quality of life in long-term Hodgkin’s disease survivors with chronic fatigue. Eur J Cancer 42(3):327–333PubMedCrossRef
27.
Joly F, Henry-Amar M, Arveux P, Reman O, Tanguy A, Peny AM, Lebailly P, Mace-Lesec’h J, Vie B, Genot JY, Busson A, Troussard X, Leporrier M (1996) Late psychosocial sequelae in Hodgkin’s disease survivors: a French population-based case-control study. J Clin Oncol 14(9):2444–2453PubMed
28.
Mols F, Vingerhoets AJ, Coebergh JW, Vreugdenhil G, Aaronson NK, Lybeert ML, van de Poll-Franse LV (2006) Better quality of life among 10–15 year survivors of Hodgkin’s lymphoma compared to 5–9 year survivors: a population-based study. Eur J Cancer 42(16):2794–2801PubMedCrossRef
29.
Norum J, Wist EA (1996) Quality of life in survivors of Hodgkin’s disease. Qual Life Res 5(3):367–374PubMedCrossRef
30.
van Tulder MW, Aaronson NK, Bruning PF (1994) The quality of life of long-term survivors of Hodgkin’s disease. Ann Oncol 5(2):153–158PubMed
31.
Wettergren L, Bjorkholm M, Axdorph U, Bowling A, Langius-Eklof A (2003) Individual quality of life in long-term survivors of Hodgkin’s lymphoma–a comparative study. Qual Life Res 12(5):545–554PubMedCrossRef
32.
Wettergren L, Bjorkholm M, Axdorph U, Langius-Eklof A (2004) Determinants of health-related quality of life in long-term survivors of Hodgkin’s lymphoma. Qual Life Res 13(8):1369–1379PubMedCrossRef
33.
Bellizzi KM, Rowland JH, Arora NK, Hamilton AS, Miller MF, Aziz NM (2009) Physical activity and quality of life in adult survivors of non-Hodgkin’s lymphoma. J Clin Oncol 27(6):960–966PubMedCrossRef
34.
Doorduijn J, Buijt I, Holt B, Steijaert M, Uyl-de Groot C, Sonneveld P (2005) Self-reported quality of life in elderly patients with aggressive non-Hodgkin’s lymphoma treated with CHOP chemotherapy. Eur J Haematol 75(2):116–123PubMedCrossRef
35.
Merli F, Bertini M, Luminari S, Mozzana R, Berte R, Trottini M, Stelitano C, Botto B, Pizzuti M, Quintana G, De Paoli A, Federico M (2004) Quality of life assessment in elderly patients with aggressive non-Hodgkin’s lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi. Haematologica 89(8):973–978PubMed
36.
Pettengell R, Donatti C, Hoskin P, Poynton C, Kettle PJ, Hancock B, Johnson S, Dyer MJ, Rule S, Walker M, Wild D (2008) The impact of follicular lymphoma on health-related quality of life. Ann Oncol 19(3):570–576PubMedCrossRef
37.
Reeve BB, Potosky AL, Smith AW, Han PK, Hays RD, Davis WW, Arora NK, Haffer SC, Clauser SB (2009) Impact of cancer on health-related quality of life of older Americans. J Natl Canc Instit 101(12):860–868CrossRef
38.
Smith SK, Crespi CM, Petersen L, Zimmerman S, Ganz PA (2010) The impact of cancer and quality of life for post-treatment non-Hodgkin lymphoma survivors. Psychooncology 19(12):1259–1267PubMedCrossRef
39.
Smith SK, Zimmerman S, Williams CS, Zebrack BJ (2009) Health status and quality of life among non-Hodgkin lymphoma survivors. Cancer 115(14):3312–3323PubMedCrossRef
40.
Vallance JK, Courneya KS, Jones LW, Reiman T (2005) Differences in quality of life between non-Hodgkin’s lymphoma survivors meeting and not meeting public health exercise guidelines. Psycho-Oncology 14(11):979–991PubMedCrossRef
41.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Canc Instit 85(5):365–376CrossRef
42.
Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med care 30(6):473–483PubMedCrossRef
43.
Browne JP, O’Boyle CA, McGee HM, McDonald NJ, Joyce CR (1997) Development of a direct weighting procedure for quality of life domains. Qual Life Res 6(4):301–309PubMedCrossRef
44.
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579PubMed
45.
Shipp M, Harrington D, Anderson J (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. The international non-hodgkin’s lymphoma prognostic factors project. New Engl J Med 329(14):987–994CrossRef
46.
van de Poll-Franse LV, Mols F, Gundy CM, Creutzberg CL, Nout RA, Verdonck-de Leeuw IM, Taphoorn MJ, Aaronson NK (2010) Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer 47(5):667–675PubMedCrossRef
47.
American cancer society (2009) Cancer facts and figures 2009. American Cancer Society, Atlanta
Metadata
Title
The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin’s and non-Hodgkin’s lymphoma survivors: a systematic review
Authors
Simone Oerlemans
Floortje Mols
Marten R. Nijziel
Marnix Lybeert
Lonneke V. van de Poll-Franse
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 9/2011
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-011-1274-4

Other articles of this Issue 9/2011

Annals of Hematology 9/2011 Go to the issue

Original Article

Radiotherapy of solitary plasmacytoma

Letter to the Editor

Genetic changes of miR-182 G106A: rather a polymorphism than a somatic mutation

Letter to the Editor

Successful treatment with bortezomib and thalidomide for POEMS syndrome

Letter to the Editor

Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients

Letter to the Editor

Combined therapy associating systemic platinum-based chemotherapy and local radiotherapy into the treatment of primary intraocular lymphoma

Original Article

Staurosporine induces megakaryocytic differentiation through the upregulation of JAK/Stat3 signaling pathway
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits